$CPIX

Cumberland Pharmaceuticals (CPIX) plans to seek FDA approval for ifetroban to treat DMD-related cardiomyopathy, using Phase 2 trial data and natural-history databases. The FDA granted a rolling review but raised concerns about evidence sufficiency. The Phase 2 trial showed a 5.4% improvement in left ventricular ejection fraction (p=0.002).

CUMBERLAND PHARMACEUTICALS INC (CPIX) filed an SEC Form 8-K — Other Events. Item 7.01 Regulation FD Disclosure. On October 26, 2026, Cumberland Pharmaceuticals Inc. (the “Company” or “Cumberland”), an innovation-focused biopharmaceutical company developing new products for rare diseases, issued a press release providing an update on its ifetroban product

CUMBERLAND PHARMACEUTICALS INC (CPIX) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events On October 23, 2026, Cumberland Pharmaceuticals Inc. (“Cumberland”) announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis. These results support the safety and tolerability of ifetroban

Cumberland Pharmaceuticals (CPIX) reported Phase 2a trial results for ifetroban in systemic sclerosis (SSc) patients. The drug was well-tolerated, with a safety profile consistent with prior studies. The trial was not designed to evaluate efficacy. Cumberland plans to submit results to the FDA and conduct further biomarker studies. SSc is a rare autoimmune disease with limited treatment options for cardiac manifestations.

Several biotech stocks hit 52-week highs on August 25, 2026. Generate Biomedicines (GENB) rose 15% to $22.67, despite a wider net loss. Biodesix (BDSX) climbed 10% to $30, reporting a 34% revenue increase. CareDx (CDNA) gained 6%, with Medicare coverage for its transplant tests. Cumberland Pharmaceuticals (CPIX) rose 10% to $8.70, advancing Ifetroban in trials. Cardiol Therapeutics (CRDL) increased 7% to $2.02, with CardiolRx in Phase 3 trials.

Biotech stocks hit 52-week highs Aug. 10 on trial and earnings updates. Silence Therapeutics (SLN) rose about 29% to $17.58 after Phase 2 SANRECO topline results for divesiran and a reduced Q2 net loss, plus an announced ~$150M ADS offering. AbCellera (ABCL) gained ~34% to $10.01 on Phase 2 ABCL635 data. Cumberland (CPIX) reached $8.45 on Phase 2 Ifetroban progress. Celldex (CLDX) rose to $43.21 on Barzolvolimab Phase 3/2 readouts. Biodesix (BDSX) hit $25.51 after Q2 revenue of $26.9M and FY gui

Cumberland Pharmaceuticals (Nasdaq: CPIX) reported Q2 2026 results and updated investors after closing a strategic transaction with Apotex Health. Apotex acquired Cumberland’s FDA-approved branded portfolio for $100 million plus $11 million for inventory and transition services. Cumberland declared a $1.50 special dividend. Q2 loss was $3.1 million from continuing operations and $4.1 million net. It reported $63 million assets and $4 million cash at June 30.

CUMBERLAND PHARMACEUTICALS INC (CPIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS $100 million Strategic Transaction Closed Special Shareholder Dividend Funded Advancing Late Stage Clinical Pipeline NASHVILLE, Tenn. (Tuesday, August 04, 2026) – Cumberland Pharmaceuticals Inc. (Nasdaq

Biotech gainers on Monday included Universe Pharmaceuticals (UPC), which reported six-month ended March 31, 2026 revenue of $9.03 million and net loss of $1.55 million, and shares rose about 99% to $6.48. Cumberland Pharma (CPIX) rose over 38% ahead of Q2 results after a $100 million branded portfolio sale. Autolus (AUTL) gained about 22% on preliminary Q2 Aucatzyl net product revenue of about $45 million. Other movers included Pulmonx (LUNG), SL Science (SLBT), CAMP4 (CAMP), and Beyond Air (XAI

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) declared a special cash dividend of $1.50 per share, payable July 31, 2026 to shareholders of record July 10, 2026. The move follows its Apotex Health strategic transaction, which provided $100 million cash and up to $11 million more. The board also authorized a $5 million buyback.